Actinium Pharmaceuticals (NYSE:ATNM) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock.

Actinium Pharmaceuticals Price Performance

ATNM opened at $1.58 on Tuesday. The stock’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.45. The stock has a market cap of $49.29 million, a P/E ratio of -1.14 and a beta of 0.10. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in Actinium Pharmaceuticals during the 3rd quarter valued at about $268,000. JPMorgan Chase & Co. increased its stake in shares of Actinium Pharmaceuticals by 804.5% during the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock worth $156,000 after purchasing an additional 110,141 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Actinium Pharmaceuticals by 413.6% during the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock worth $155,000 after purchasing an additional 99,158 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Actinium Pharmaceuticals by 49.9% during the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at approximately $112,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).